| Sandoz Pharmaceuticals AG - Bupropion XR Sandoz 300 mg, Retardtabletten | | 68628 | | 02 | | Bupropion XR Sandoz 300 mg | | Retardtabletten | | N06AX12 | | Bupropion | | 12.12.2023 | | |
| | Composition | | bupropioni hydrochloridum 300 mg, povidonum K 90, cysteini hydrochloridum monohydricum, silica colloidalis anhydrica, glyceroli dibehenas, magnesii stearas, Überzug: ethylcellulosum, povidonum K 90, macrogolum 1450, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii laurilsulfas corresp. natrium 0.005 mg, polysorbatum 80, silica colloidalis hydrica, triethylis citras, Drucktinte: lacca, E 172 (nigrum), alcohol butylicus, propylenglycolum, ammoniae solutio 28 per centum, pro compresso obducto. | | Packungsbestandteile | | Comprimés retards | | | | Principe actif | Concentr. |
|---|
| Bupropion Hydrochloride | 300 mg |
| | | | Agents auxilliaires | Concentr. | informations additionels |
|---|
| (Nigrum) | | | | Acidi Methacrylici | | | | Alcohol Butylicus | | | | Ammoniae Solutio | 28 | | | Cystein Hydrochloride Monohydrate | | | | E 172 | | color. | | Ethylcellulosum | | Überzug | | Ethylis Acrylatis Polymerisatum | | | | Glyceroli Dibehenas | | | | Lacca | | Drucktinte | | Macrogol | 1450 | | | Magnesii Stearas | | | | Natrii Laurilsulfas | | | | Per Centum | | | | Polysorbatum 80 | | | | Povidonum K | 90 | | | Pro Compresso Obducto | | | | Propylenglycol | | | | Silica Colloidalis Anhydrica | | | | Silica Colloidalis Hydrica | | | | Triethylis Citras | | |
|
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 003 | 30 | DDP | DDP | B | | Non |
|
|
